Literature DB >> 23123095

An expanding range of targets for kynurenine metabolites of tryptophan.

Trevor W Stone1, Nicholas Stoy, L Gail Darlington.   

Abstract

The kynurenine pathway of tryptophan metabolism accounts for most of the tryptophan that is not committed to protein synthesis and includes compounds active in the nervous and immune systems. Kynurenine acts on the aryl hydrocarbon receptor, affecting the metabolism of xenobiotics and promoting carcinogenesis. Quinolinic acid is an agonist at N-methyl-D-aspartate receptors (NMDARs), but is also pro-oxidant, has immunomodulatory actions, and promotes the formation of hyperphosphorylated tau proteins. Kynurenic acid blocks NMDARs and α7-homomeric nicotinic cholinoceptors and is also an agonist at the orphan G-protein-coupled receptor GPR35. 3-Hydroxykynurenine and 3-hydroxyanthranilic acid have pronounced redox activity and regulate T cell function. Cinnabarinic acid can activate metabotropic glutamate receptors. This review highlights the increasing range of molecular targets for components of the kynurenine pathway in both the nervous and immune systems in relation to their relevance to disease and drug development.
Copyright © 2012. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23123095     DOI: 10.1016/j.tips.2012.09.006

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  112 in total

1.  Tryptophan 2,3-dioxygenase and indoleamine 2,3-dioxygenase 1 make separate, tissue-specific contributions to basal and inflammation-induced kynurenine pathway metabolism in mice.

Authors:  Paul B Larkin; Korrapati V Sathyasaikumar; Francesca M Notarangelo; Hiroshi Funakoshi; Toshikazu Nakamura; Robert Schwarcz; Paul J Muchowski
Journal:  Biochim Biophys Acta       Date:  2016-07-05

2.  What is the tryptophan kynurenine pathway and why is it important to neurotherapeutics?

Authors:  Ian Davis; Aimin Liu
Journal:  Expert Rev Neurother       Date:  2015-05-24       Impact factor: 4.618

3.  Inhibition of kynurenine aminotransferase II attenuates hippocampus-dependent memory deficit in adult rats treated prenatally with kynurenine.

Authors:  Ana Pocivavsek; Greg I Elmer; Robert Schwarcz
Journal:  Hippocampus       Date:  2018-12-04       Impact factor: 3.899

Review 4.  Aryl hydrocarbon receptor ligands in cancer: friend and foe.

Authors:  Iain A Murray; Andrew D Patterson; Gary H Perdew
Journal:  Nat Rev Cancer       Date:  2014-12       Impact factor: 60.716

Review 5.  Kynurenic Acid in Schizophrenia: A Systematic Review and Meta-analysis.

Authors:  Eric Plitman; Yusuke Iwata; Fernando Caravaggio; Shinichiro Nakajima; Jun Ku Chung; Philip Gerretsen; Julia Kim; Hiroyoshi Takeuchi; M Mallar Chakravarty; Gary Remington; Ariel Graff-Guerrero
Journal:  Schizophr Bull       Date:  2017-07-01       Impact factor: 9.306

Review 6.  Kynurenic acid as an antagonist of α7 nicotinic acetylcholine receptors in the brain: facts and challenges.

Authors:  Edson X Albuquerque; Robert Schwarcz
Journal:  Biochem Pharmacol       Date:  2012-12-25       Impact factor: 5.858

7.  Strategic Incorporation of Polarity in Heme-Displacing Inhibitors of Indoleamine-2,3-dioxygenase-1 (IDO1).

Authors:  Catherine White; Meredeth A McGowan; Hua Zhou; Nunzio Sciammetta; Xavier Fradera; Jongwon Lim; Elizabeth M Joshi; Christine Andrews; Elliott B Nickbarg; Phillip Cowley; Sarah Trewick; Martin Augustin; Konstanze von Köenig; Charles A Lesburg; Karin Otte; Ian Knemeyer; Hyun Woo; Wensheng Yu; Mangeng Cheng; Peter Spacciapoli; Prasanthi Geda; Xuelei Song; Nadya Smotrov; Patrick Curran; Mee Ra Heo; Pravien Abeywickrema; J Richard Miller; David Jonathan Bennett; Yongxin Han
Journal:  ACS Med Chem Lett       Date:  2020-03-10       Impact factor: 4.345

8.  Neuroprotective kynurenine metabolite indices are abnormally reduced and positively associated with hippocampal and amygdalar volume in bipolar disorder.

Authors:  Jonathan Savitz; Robert Dantzer; Brent E Wurfel; Teresa A Victor; Bart N Ford; Jerzy Bodurka; P S F Bellgowan; T Kent Teague; Wayne C Drevets
Journal:  Psychoneuroendocrinology       Date:  2014-11-24       Impact factor: 4.905

9.  Aryl hydrocarbon receptor control of a disease tolerance defence pathway.

Authors:  Alban Bessede; Marco Gargaro; Maria T Pallotta; Davide Matino; Giuseppe Servillo; Cinzia Brunacci; Silvio Bicciato; Emilia M C Mazza; Antonio Macchiarulo; Carmine Vacca; Rossana Iannitti; Luciana Tissi; Claudia Volpi; Maria L Belladonna; Ciriana Orabona; Roberta Bianchi; Tobias V Lanz; Michael Platten; Maria A Della Fazia; Danilo Piobbico; Teresa Zelante; Hiroshi Funakoshi; Toshikazu Nakamura; David Gilot; Michael S Denison; Gilles J Guillemin; James B DuHadaway; George C Prendergast; Richard Metz; Michel Geffard; Louis Boon; Matteo Pirro; Alfonso Iorio; Bernard Veyret; Luigina Romani; Ursula Grohmann; Francesca Fallarino; Paolo Puccetti
Journal:  Nature       Date:  2014-07-10       Impact factor: 49.962

10.  Efficacy of N-Acetylserotonin and Melatonin in the EAE Model of Multiple Sclerosis.

Authors:  Jie Wen; Prasanth S Ariyannur; Rachel Ribeiro; Mikiei Tanaka; John R Moffett; Batool F Kirmani; Aryan M A Namboodiri; Yumin Zhang
Journal:  J Neuroimmune Pharmacol       Date:  2016-08-25       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.